AZD3759治疗EGFR突变伴中枢神经系统转移非小细胞肺癌的I期BLOOM研究
BLOOM是一项在11个中心开展的开标签I期研究,评估AZD3759在EGFR突变晚期NSCLC伴脑或脑膜转移患者中的安全性、耐受性、药代动力学和疗效。剂量递增阶段入组29例,剂量扩展阶段入组38例;500 mg每日两次出现剂量限制性毒性,故扩展阶段选用200 mg或300 mg每日两次。AZD3759 200 mg每日两次安全性可耐受,血脑屏障穿透性好且临床活性令人鼓舞。
要点
- AZD3759 200 mg每日两次在EGFR突变NSCLC伴CNS转移患者中安全性可耐受
- 500 mg每日两次出现剂量限制性毒性,扩展阶段选用200 mg或300 mg每日两次
- AZD3759血脑屏障穿透性好且临床活性令人鼓舞,支持进一步研究
核心结论
- AZD3759 200 mg每日两次在未接受或已接受TKI治疗的NSCLC伴CNS转移患者中安全性可耐受。
- AZD3759血脑屏障穿透性好且临床活性令人鼓舞,支持进一步评估。
研究设计与样本
- 开标签、多中心、I期研究,在澳大利亚、韩国、台湾和美国的11个中心及医院开展。
- 研究分剂量递增和剂量扩展两部分;递增阶段既往TKI进展患者接受50、100、200、300或500 mg每日两次。
- 扩展阶段未接受TKI的脑或脑膜转移患者及既往TKI治疗的脑膜转移患者接受200 mg或300 mg每日两次。
- 2014年11月18日至2016年9月7日共入组67例NSCLC患者,递增阶段29例,扩展阶段38例。
- 主要目标为安全性和耐受性,不良事件严重程度按NCI CTCAE 4.03评估。
主要发现
- 数据截止2016年12月12日,递增阶段3例(10%)和扩展阶段20例(53%)仍在接受治疗。
- 递增阶段500 mg每日两次的3例中2例(67%)出现剂量限制性毒性(3级痤疮1例,不可耐受的2级黏膜炎1例)。
- 扩展阶段任何级别药物相关皮肤和胃肠道疾病分别发生于35例(92%)和29例(76%)。
- 扩展阶段200 mg每日两次组3级皮肤和胃肠道疾病分别4例(17%)和2例(9%),300 mg组分别6例(40%)和4例(27%),无4级疾病。
- 因治疗相关不良事件停药:200 mg组1例(4%,3级ALT和AST升高),300 mg组2例(13%,3级腹泻1例、3级皮疹1例)。
关键数值与推荐
- 剂量限制性毒性发生于500 mg每日两次的3例中2例(67%),据此扩展阶段选用200 mg和300 mg每日两次。
- 扩展阶段任何级别药物相关皮肤疾病35例(92%),胃肠道疾病29例(76%)。
- 200 mg每日两次组3级皮肤疾病4例(17%)、胃肠道疾病2例(9%);300 mg组分别为6例(40%)和4例(27%)。
- 其他3级疾病:200 mg组肝胆和肾脏疾病3例(13%)、代谢和营养疾病1例(4%);300 mg组乏力1例(7%)、感染1例(7%)、代谢和营养疾病1例(7%)。
- 因不良事件停药:200 mg组1例(4%),300 mg组2例(13%)。
临床怎么用
- 对EGFR突变NSCLC伴脑或脑膜转移患者,AZD3759 200 mg每日两次是安全性可耐受的候选剂量。
- 500 mg每日两次因剂量限制性毒性不宜直接用于扩展研究。
- 用药期间需重点监测皮肤、胃肠道、肝胆和肾脏不良事件。
局限性
- 本研究为I期、开标签、非随机研究,样本量67例。
- 数据截止时递增阶段和扩展阶段分别仅3例(10%)和20例(53%)仍在治疗。
- 研究未设对照组,疗效需进一步研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CNS metastases-including brain and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with poor prognosis. AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood-brain barrier. We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in patients with EGFR-mutant NSCLC with brain and leptomeningeal metastases. METHODS: This open-label, multicentre, phase 1 study was undertaken at 11 centres and hospitals in Australia, South Korea, Taiwan, and the USA. Eligible patients included those with histologically confirmed, advanced-stage, EGFR-mutant NSCLC. The study was done in two parts, with dose-escalation and dose-expansion phases. In the dose-escalation phase, patients who had progressed after treatment with an EGFR tyrosine kinase inhibitor received AZD3759 at 50 mg, 100 mg, 200 mg, 300 mg, or 500 mg twice a day. In the dose-expansion phase, AZD3759 at 200 mg or 300 mg twice a day was administered to patients with either brain or leptomeningeal metastases who had never received an EGFR tyrosine kinase inhibitor and patients with leptomeningeal metastases who had been pretreated with an EGFR tyrosine kinase inhibitor. The primary objective was safety and tolerability, with severity of adverse events assessed with the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03. This trial is registered with ClinicalTrials.gov, number NCT02228369. FINDINGS: Between Nov 18, 2014, and Sept 7, 2016, 67 patients with NSCLC were enrolled into the study, 29 to the dose-escalation phase and 38 to the dose-expansion phase. At data cutoff (Dec 12, 2016), three (10%) patients in the dose-escalation phase and 20 (53%) in the dose-expansion phase were still receiving treatment. Dose-limiting toxic effects occurred in two (67%) of three patients who received 500 mg twice a day in the dose-escalation phase (grade 3 acne [n=1] and intolerable grade 2 mucosal inflammation [n=1]); hence, doses of 200 mg and 300 mg twice a day were selected for further assessment in the dose-expansion phase. Drug-related skin and gastrointestinal disorders of any grade occurred in 35 (92%) and 29 (76%) patients in the dose-expansion phase, respectively, and led to treatment discontinuation in one (4%) patient treated with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given 300 mg twice a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]). Grade 3 skin and gastrointestinal disorders occurred in four (17%) and two (9%) patients, respectively, at a dose of 200 mg twice a day, and in six (40%) and four (27%) patients, respectively, at a dose of 300 mg twice a day. No grade 4 disorders arose. Other grade 3 disorders included hepatobiliary and renal disorders (three [13%] at 200 mg twice a day), asthenia (one [7%] at 300 mg twice a day), infections and infestations (one [7%] at 300 mg twice a day), and metabolism and nutrition disorders (one [4%] at 200 mg twice a day and one [7%] at 300 mg twice a day). INTERPRETATION: AZD3759 at a dose of 200 mg twice daily showed a tolerable safety profile in patients with NSCLC and CNS metastases who had either never received a tyrosine kinase inhibitor or who had been pretreated with a tyrosine kinase inhibitor. The good penetration of the blood-brain barrier by AZD3759, and its promising clinical activity, support further assessment of this compound in studies. FUNDING: AstraZeneca.
引用
- Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017. PMID: 29056570. doi:10.1016/S2213-2600(17)30378-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。